Mapping Hengrun's GLP-1 Global Expansion: A $6 Billion Journey
License out/in
In a landmark move, China's pharmaceutical giant Hengrun has licensed out the global development, manufacturing and commercialization rights (excluding Greater China) of its three innovative GLP-1 drugs to the newly-founded US biotech company Hercules. This $6 billion deal marks a significant step in Hengrun's international expansion strategy.
The licensed GLP-1 assets include HRS-7535, HRS-9531, and HRS-4729. Hercules, a $400 million startup backed by leading investors like Bain Capital Life Sciences, Atlas Ventures, RTW Capital and Lyra Capital, will pay Hengrun an upfront payment and near-term milestones totaling $110 million. Additional clinical, regulatory and sales milestones could reach up to $220 million and $5.725 billion respectively, along with tiered royalties on net sales.
Notably, Hengrun will also acquire a 19.9% equity stake in Hercules as part of the deal, a departure from typical license-out transactions. The two companies will establish a joint steering committee to coordinate the global development and commercialization of the licensed products.
This deal represents Hengrun's accelerated pursuit of global expansion amidst the dual pressures of limited payment terms and internal R&D challenges faced by domestic Chinese pharma firms in recent years. After establishing a US subsidiary in 2022, Hengrun has now embraced the mainstream "license-out" strategy adopted by domestic biotech companies to partner with international players and expand overseas.
In 2023 alone, Hengrun announced five out-licensing agreements worth over $4 billion. The latest GLP-1 transaction builds on these efforts, allowing Hengrun to not only secure upfront and milestone payments, but also gain a strategic stake in the platform created by Hercules to further drive its global market access.
The surging interest in GLP-1 therapies for weight management and diabetes, driven by recent market successes, has fueled a frenzy of deal-making in this space. Hengrun's $6 billion licensing agreement underscores the immense commercial potential of its GLP-1 portfolio as it seeks to expand its footprint in the lucrative global markets.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.